HomeGeneticsConditionMultiminicore disease
Back to Condition
Multiminicore disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Multiminicore disease

Multiminicore disease is a rare muscle disorder characterized by skeletal muscle weakness and the presence of small, disorganized regions called minicores within muscle cells.

Overview

Multiminicore disease primarily affects skeletal muscles, causing weakness that ranges from mild to life-threatening. The condition is named for the "minicores"—small, disorganized areas found in muscle cells when viewed under a microscope—which are often present in cells with few or no mitochondria.

Types

There are four recognized forms of the disease:

  • Classic form: Accounts for 75% of cases; involves weakness in the torso and neck, "floppy" infants, and potential respiratory issues or spinal curvature (scoliosis).
  • Progressive form with hand involvement: Involves muscle weakness and joint laxity in the arms and hands, often with exercise intolerance.
  • Antenatal form with arthrogryposis: Characterized by rigid joints throughout the body and distinctive facial features.
  • Ophthalmoplegic form: Characterized by paralysis of the eye muscles, leading to abnormal eye movements and droopy eyelids.

Causes & Risk Factors

Variants in the SELENON and RYR1 genes cause about half of all cases. SELENON variants are linked to the classic form and may affect muscle formation and calcium balance. RYR1 variants disrupt the ryanodine receptor 1 protein, which regulates calcium release in muscle cells, preventing normal contraction. Individuals with these variants may also be at risk for malignant hyperthermia, a severe reaction to certain anesthetic gases used during surgery.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have variants. Parents of an affected individual typically carry one copy of the altered gene but do not show symptoms.

Frequently Asked Questions

Both parents would be carriers, giving a 25 % chance that a child inherits two mutated copies. Prenatal testing can be done via chorionic villus sampling (around 10–12 weeks) or amniocentesis (after 15 weeks) to detect the specific mutation. Pre‑implantation genetic diagnosis (PGD) during IVF is another option to select embryos without the disease‑causing variants.
Watch for sudden worsening of breathing, especially during sleep or after exertion. Look for rapid breathing, wheezing, cyanosis (bluish lips or skin), persistent coughing, or a feeling of tightness in the chest. If any of these occur, seek emergency care promptly, as respiratory failure can develop quickly in affected children.
SELENON mutations disrupt the protein that helps regulate calcium balance in muscle cells, leading to impaired muscle contraction and increased susceptibility to fatigue. Physical therapy focused on gentle, low‑impact strengthening and stretching can improve muscle endurance. Some patients benefit from calcium‑channel modulators or antioxidant supplements, but these should only be used under a specialist’s guidance.
Patients with RYR1 mutations are at risk for malignant hyperthermia, a life‑threatening reaction to certain anesthetic gases. Use total intravenous anesthesia (TIVA) with agents like propofol, avoid volatile anesthetics and succinylcholine, and have dantrolene immediately available. A detailed anesthetic plan should be shared with the surgical team well before the procedure.===
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA